MDMA (Ecstasy)

GPTKB entity

Statements (71)
Predicate Object
gptkbp:instanceOf recreational drug
gptkbp:abusePotential moderate
gptkbp:alsoKnownAs gptkb:Molly
gptkb:Ecstasy
gptkb:3,4-methylenedioxymethamphetamine
gptkbp:aroma odorless
gptkbp:ATCCode none
gptkbp:boilingPoint not well defined (decomposes)
gptkbp:CASNumber 42542-10-9
gptkbp:chemicalFormula C11H15NO2
gptkbp:color white (pure form)
gptkbp:commonAdulterants gptkb:MDA
gptkb:PMMA
amphetamine
caffeine
gptkbp:controlledBy gptkb:United_Nations_Convention_on_Psychotropic_Substances
gptkbp:discoveredBy gptkb:Anton_Köllisch
gptkbp:discoveredIn 1912
gptkbp:drugClass psychedelic
entactogen
stimulant
gptkbp:effect euphoria
increased empathy
increased sociability
enhanced sensations
gptkbp:excretion kidneys
gptkbp:firstSynthesized gptkb:Merck
gptkbp:halfLife 7 hours
https://www.w3.org/2000/01/rdf-schema#label MDMA (Ecstasy)
gptkbp:IUPACName 1-(1,3-benzodioxol-5-yl)-N-methylpropan-2-amine
gptkbp:legalStatus gptkb:Schedule_I_(US)
gptkb:Class_A_(UK)
illegal in most countries
gptkbp:mechanismOfAction serotonin releasing agent
dopamine releasing agent
norepinephrine releasing agent
gptkbp:meltingPoint 148–149 °C
gptkbp:metabolism liver
gptkbp:molecularWeight 193.25 g/mol
gptkbp:overdoseSymptoms gptkb:arrhythmia
seizures
hyperthermia
hyponatremia
gptkbp:proposedMedicalUse PTSD treatment (investigational)
anxiety in terminal illness (investigational)
gptkbp:PubChem_CID 1615
CHEMBL43019
gptkbp:riskOfAdulteration high
gptkbp:routeOfAdministration oral
intravenous
insufflation
gptkbp:sideEffect anxiety
dehydration
insomnia
hyperthermia
jaw clenching
depression (after use)
gptkbp:solubility soluble in water
gptkbp:streetForm gptkb:tablet
capsule
crystal
powder
gptkbp:toxicity neurotoxic at high doses
gptkbp:UNII J1DOI7UV76
gptkbp:usedFor recreational purposes
psychotherapy (experimental)
gptkbp:usedIn music festivals
rave culture
dance clubs
gptkbp:bfsParent gptkb:Schedule_1
gptkbp:bfsLayer 7